| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.02 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.03 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.03 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.03 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.092 | 0.03 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.074 | 0.03 |